101 related articles for article (PubMed ID: 20408837)
1. Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma.
Servais S; Caers J; Warling O; Frusch N; Baron F; De Prijck B; Beguin Y
Br J Haematol; 2010 Aug; 150(3):379-81. PubMed ID: 20408837
[No Abstract] [Full Text] [Related]
2. Enterovirus infection of neuronal cells post-Rituximab.
Kiani-Alikhan S; Skoulidis F; Barroso A; Nuovo G; Ushiro-Lumb I; Breuer J; Lister A; Mattes F
Br J Haematol; 2009 Aug; 146(3):333-5. PubMed ID: 19466969
[No Abstract] [Full Text] [Related]
3. Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy.
Ganjoo KN; Raman R; Sobel RA; Pinto HA
Leuk Lymphoma; 2009 Apr; 50(4):673-5. PubMed ID: 19373672
[No Abstract] [Full Text] [Related]
4. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
Quartier P; Tournilhac O; Archimbaud C; Lazaro L; Chaleteix C; Millet P; Peigue-Lafeuille H; Blanche S; Fischer A; Casanova JL; Travade P; Tardieu M
Clin Infect Dis; 2003 Feb; 36(3):e47-9. PubMed ID: 12539090
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in diffuse large B-cell lymphoma.
Coiffier B
Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
[No Abstract] [Full Text] [Related]
6. Enteroviral encephalitis in a patient with a marginal zone lymphomatreated with rituximab.
Schilthuizen C; Berenschot HW; Levin MD
Neth J Med; 2010 May; 68(5):221-3. PubMed ID: 20508271
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
9. Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab.
Padate BP; Keidan J
Clin Lab Haematol; 2006 Feb; 28(1):69-71. PubMed ID: 16430465
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus gastritis after treatment with rituximab.
Hasegawa Y; Goto A; Nishimura S; Sukawa Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Shinomura Y; Yoshida Y
Endoscopy; 2009; 41 Suppl 2():E199. PubMed ID: 19637127
[No Abstract] [Full Text] [Related]
11. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
12. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma.
Ozgönenel B; Moonka D; Savaşan S
Am J Hematol; 2006 Apr; 81(4):302. PubMed ID: 16550511
[No Abstract] [Full Text] [Related]
13. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M; Yamamoto G; Imai Y; Kurokawa M
Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
[No Abstract] [Full Text] [Related]
14. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
15. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
Miles SA; McGratten M
J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
[No Abstract] [Full Text] [Related]
16. Disseminated Enteroviral Infection Associated with Obinutuzumab.
Dendle C; Gilbertson M; Korman TM; Golder V; Morand E; Opat S
Emerg Infect Dis; 2015 Sep; 21(9):1661-3. PubMed ID: 26291712
[TBL] [Abstract][Full Text] [Related]
17. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
[TBL] [Abstract][Full Text] [Related]
18. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient.
Aksoy S; Abali H; Kilickap S; Erman M; Kars A
Clin Lab Haematol; 2006 Jun; 28(3):211-4. PubMed ID: 16706940
[TBL] [Abstract][Full Text] [Related]
19. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
20. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
Sohani AR; Ferry JA; Chang PS; Abramson JS
J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
